Palatin Technologies (PTN) Non-Current Assets (2011 - 2026)
Palatin Technologies' (PTN) quarterly Non-Current Assets came in at $440089.0 in Q1 2026, down 11.13% YoY from $495216.0 in Q1 2025, and down 4.38% on a QoQ basis from $460249.0 in Q4 2025.
Palatin Technologies (PTN) Non-Current Assets (2011 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 15 years of Non-Current Assets data on file, last reported at $440089.0 in Q1 2026.
- Quarterly Non-Current Assets fell 11.13% year-over-year to $440089.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (down 48.72% YoY) and the FY2025 annual result came in at $347526.0, down 64.27% from the prior year.
- Non-Current Assets declined to $440089.0 in Q1 2026, from $460249.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $1.6 million in Q2 2023 to a low of $244882.0 in Q3 2025.
- A 5-year average of $1.0 million and a median of $1.1 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets rose 9.71% — and 2025, when it sank 69.49%.
- Tracing PTN's Non-Current Assets over 5 years: stood at $1.4 million in 2022, then retreated by 8.13% to $1.3 million in 2023, then tumbled by 51.1% to $640301.0 in 2024, then slipped by 28.12% to $460249.0 in 2025, then decreased by 4.38% to $440089.0 in 2026.
- The last three Non-Current Assets figures came in at $440089.0 (Q1 2026), $460249.0 (Q4 2025), and $244882.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Palatin Technologies | 40.86 Mn | 40.86 Mn | - | 440,089.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 440,089.00 |
| Dec 31, 2025 | 460,249.00 |
| Sep 30, 2025 | 244,882.00 |
| Jun 30, 2025 | 347,526.00 |
| Mar 31, 2025 | 495,216.00 |
| Dec 31, 2024 | 640,301.00 |
| Sep 30, 2024 | 802,610.00 |
| Jun 30, 2024 | 972,598.00 |
| Mar 31, 2024 | 1.14 Mn |
| Dec 31, 2023 | 1.31 Mn |
| Sep 30, 2023 | 1.44 Mn |
| Jun 30, 2023 | 1.62 Mn |
| Mar 31, 2023 | 1.37 Mn |
| Dec 31, 2022 | 1.43 Mn |
| Sep 30, 2022 | 1.46 Mn |
| Jun 30, 2022 | 1.47 Mn |
| Mar 31, 2022 | 1.57 Mn |
| Dec 31, 2021 | 1.63 Mn |
| Sep 30, 2021 | 1.34 Mn |
| Jun 30, 2021 | 1.39 Mn |